A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19

PHASE3TerminatedINTERVENTIONAL
Enrollment

191

Participants

Timeline

Start Date

July 12, 2020

Primary Completion Date

December 28, 2020

Study Completion Date

January 22, 2021

Conditions
COVID-19CoronavirusCoronavirus Infection
Interventions
COMBINATION_PRODUCT

INOpulse

Subjects will be treated by means of an INOpulse device using an INOpulse nasal cannula.

COMBINATION_PRODUCT

Placebo

Subjects will be treated by means of an INOpulse device using an INOpulse nasal cannula.

Trial Locations (17)

19140

Temple University Hospital, Philadelphia

22042

INOVA, Falls Church

23114

St. Francis Medical Center, Richmond

23116

Memorial Regional Medical Center, Richmond

23225

Chippenham Medical Center, Richmond

23226

Pulmonary Associates of Richmond, Richmond

St. Mary's Hospital, Richmond

23235

Johnston-Willis Hospital, Richmond

33136

University of Miami Health System, Miami

43210

The Ohio State University Wexner Medical Center, Columbus

43608

Mercy Health St. Vincent Medical Center, Toledo

63017

The Lung Research Center (St. Luke's), Chesterfield

77030

Houston Methodist, Houston

85006

Banner University Medical Center, Phoenix

87106

University of New Mexico Hospital, Albuquerque

92120

Kaiser Permanente - Zion Medical Center, San Diego

92123

Kaiser Permanente - San Diego Medical Center, San Diego

Sponsors
All Listed Sponsors
lead

Bellerophon Pulse Technologies

INDUSTRY